The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Rapid monitoring of CQAs for therapeutic mAbs is a critical need to support the rapid growth in the commercial and clinical mAb pipeline. Until recently, there has not been a single analytical tool that could provide rapid, quantitative, and high-resolution charge variant analysis along with the molecular mass identification of peaks. The Blaze system provides a single characterization method to enable iCIEF-MS analysis of mAbs, all in a 15-minute assay1.
We will demonstrate the unique capability of the Blaze iCIEF system to directly identify cIEF-separated peaks by mass spectrometry of adalumimab, a therapeutic antibody. The Blaze analysis was interfaced with the TripleTOF® 6600+ Quadrupole Time-Of-Flight (QTOF) from SCIEX and data was analyzed using a new Blaze iCIEF-MS workflow in Protein Metrics Byos® software, developed specifically for the Blaze data. Advancements in method development will be described that enabled the identification of glycation, succinimide intermediates, unprocessed C-terminal lysine, and the N-glycan profile for each of these identified proteoforms, as well as other late breaking results.
1Mack, S., et al. (2019). Electrophoresis, 40(23-24), 3084-3091